title: New therapies for gout.
abstract: Gout prevalence is increasing, yet management remains suboptimal. Fortunately, new insights into gout biology are permitting the development of novel, potentially more effective strategies for both gouty inflammation and urate lowering. Colchicine, a drug long used for gout, has been recently approved (for the first time ever) by the FDA, based on a new, safer dosing regimen. The recently appreciated centrality of IL-1β in acute gouty inflammation has prompted studies of agents blocking the IL-1β receptor or soluble IL-1β signaling (canakinumab, rilonacept, anakinra). Novel approaches to urate lowering have led to mechanism-based therapies such as urate synthesis inhibitors (febuxostat is already FDA approved and BCX4208 is in development), URAT-1 inhibitors promoting renal uric acid excretion (lesinurad), and recombinant uricase to directly catabolize urate (pegloticase). These new treatments do not obviate the need for lifestyle and dietary management, another area in which significant scientific and clinical progress has recently been made.
authors: Crystal Diseases Study Group, Division of Rheumatology, Department of Medicine, NYU School of Medicine/NYU Langone Medical Center, New York, New York 10003, USA. daria.crittenden@nyumc.org
authors: Daria B
authors: DB
authors: Crittenden
authors: Michael H
authors: MH
authors: Pillinger
mesh_terms: D016207:Cytokines / Q000037:antagonists & inhibitors*; D017277:Drug Approval; D006073:Gout / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D015995:Prevalence; D014481:United States / Q000453:epidemiology
chemical_list: D016207:Cytokines; D006074:Gout Suppressants